Consistent exosome production is a core bioengineering milestone that underpins clinical-grade manufacturing. This independent assessment provides additional evidence of our manufacturing process ...
TORONTO and HAIFA, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce significant ...
TORONTO and HAIFA, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a ...
TORONTO and HAIFA, Israel, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a ...
cell-derived exosomes in large scale bioreactors in partnership with the French Blood Establishment (EFS) with unprecedented yields The disruptive, proprietary technology developed by EVerZom offers a ...
TORONTO and HAIFA, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is ...
There's a lot we don't know, and one thing experts know for certain.
At the end of January, EXO Biologics in Belgium launched ExoXpert. This contract development and manufacturing organization (CDMO), which is a subsidiary of EXO, provides exosomes to accelerate the ...
Within this global landscape, the EXO 001 targeted exosome platform—developed jointly by CMUH and Ever Supreme Bio Technology—stands out for its use of high-biocompatibility, naturally derived ...
In response to chronic stimuli such as alcohol abuse, viral infection, NAFLD/NASH and toxic damage, liver loses its normal structure and non-parenchymal cells including HSCs, KCs and LSECs undergo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results